Ludwig Institute For Cancer Research (LICR) Issues Statement Concerning Prospect Therapeutics, Inc.'s GCS-100 Molecule
6/5/2009 10:45:04 AM
More...
|
Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
5/26/2009 9:03:08 AM
More...
|
Prospect Therapeutics, Inc.'s GCS-100 Exhibits a Low Toxicity Profile in Cancer Patients
5/20/2009 8:50:56 AM
More...
|
Prospect Therapeutics, Inc. Assigns All Its Assets for the Benefit of Its Creditors
5/13/2009 8:26:53 AM
More...
|